BioRestorative Therapies, Inc.
Nasdaq · CIK 0001505497 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$23,170
Cost Of Revenue
$7,385
Gross Profit
$15,785
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $23,170 | - | - |
| Cost Of Revenue | $7,385 | - | - |
| Gross Profit | $15,785 | - | - |
| Operating Income | $-3.4M | - | - |
| Net Income | $-2.2M | - | - |
| Eps Basic | -0.12 | - | - |
| Eps Diluted | -0.12 | - | - |
| Cash And Equivalents | $3.1M | - | - |
| Total Assets | $4.6M | - | - |
| Shareholders Equity | $3.0M | - | - |
| Operating Cash Flow | $-3.8M | - | - |
| Capital Expenditures | $36,400 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | BioRestorative Therapies, Inc. | 2026-05-14 | 0001493152-26-023126 |
| 10-K | BioRestorative Therapies, Inc. | 2026-03-26 | 0001493152-26-012925 |
| 10-Q | BioRestorative Therapies, Inc. | 2025-11-12 | 0001493152-25-021993 |
| 4 | BioRestorative Therapies, Inc. | 2025-10-20 | 0001021771-25-000141 |
| 4 | BioRestorative Therapies, Inc. | 2025-10-20 | 0001021771-25-000140 |
| 10-Q | BioRestorative Therapies, Inc. | 2025-08-12 | 0001641172-25-023211 |